Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Adiponectin: a new adipocytokine].

E Lebas1, N Paquot, A J Scheen

  • 1Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine, CHU Sart Tilman, Liège.

Revue Medicale De Liege
|November 25, 2003
PubMed
Summary

Adiponectin, an adipose-specific protein, is reduced in obesity and type 2 diabetes. Increasing adiponectin levels may offer a new treatment for insulin resistance and diabetes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007

Area of Science:

  • Metabolic research
  • Endocrinology
  • Molecular biology

Context:

  • Adipose tissue functions beyond energy storage, secreting adipocytokines like TNF-alpha, leptin, and adiponectin that regulate systemic metabolism.
  • Adiponectin, a key adipocytokine, has its gene located on chromosome 3q27, a region linked to type 2 diabetes and metabolic syndrome.
  • Unlike other adipocytokines, adiponectin levels decrease in obesity and type 2 diabetes, highlighting its unique role.

Purpose:

  • To investigate the role of adiponectin in metabolic regulation.
  • To explore the therapeutic potential of adiponectin for metabolic disorders.

Summary:

  • Adiponectin is an adipose-specific protein with reduced levels in obesity and type 2 diabetes.
  • Thiazolidinediones, PPARs-gamma ligands, increase plasma adiponectin, potentially improving insulin sensitivity.
  • Administration of adiponectin presents a potential novel therapeutic strategy for insulin resistance and type 2 diabetes.

Impact:

  • Adiponectin's unique expression pattern and its link to metabolic syndrome suggest it as a crucial factor in metabolic health.
  • Modulating adiponectin levels could lead to new therapeutic interventions for widespread metabolic diseases.
  • This research opens avenues for developing treatments targeting adiponectin pathways for type 2 diabetes and insulin resistance.

Related Experiment Videos